TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial

Next Previous
Trial Profile

TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms TAS-CC4 Study

    • Most Recent Events

    • 05 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top